FitLife Brands, Inc.

NASDAQ•FTLF

CEO: Mr. Dayton Robert Judd CPA

Sector: Consumer Defensive

Industry: Packaged Foods

Listing Date: 2007-11-02

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Contact Information

5214 South 136th Street, Omaha, NE, 68137, United States

402-991-5618

www.fitlifebrands.com

Market Cap

$138.33M

P/E (TTM)

20.5

10.6

Dividend Yield

52W High

$20.98

52W Low

$9.83

52W Range

44%

Rank33Top 25.7%

4.8

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Average • 4.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$23.49M+46.99%

4-Quarter Trend

EPS

$0.10-56.52%

4-Quarter Trend

FCF

$3.66M+78.99%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Jumps Post-Acquisition Quarterly revenue reached $23,485K, surging 47% compared to prior period. Nine month revenue $55,548K, up 12%.

Gross Profit Rises 25% Q3 Gross Profit totaled $8,736K, a 25% increase driven by Irwin acquisition volume and higher MusclePharm sales.

Total Assets Nearly Double Total Assets grew to $109,984K by September 30, 2025, significantly higher than $58,531K reported December 31, 2024.

Net Income Falls Sharply Q3 Net Income $921K decreased 57% versus prior year, impacted by $820K merger expense and lower gross margin.

Risk Factors

Gross Margin Pressure Continues Q3 Gross Margin dropped 6.6 points to 37.2% due to lower margin Irwin sales and $392K inventory step-up amortization.

High Acquisition Expenses Nine month Merger and Acquisition expense reached $1,848K, primarily transaction costs related to the recent Irwin acquisition.

Increased Debt Load Total Liabilities rose to $68,092K, supported by $40,625K outstanding Irwin Term Loan debt following August acquisition funding.

Goodwill Impairment Potential Stock price volatility impacts goodwill valuation; management notes potential impairment if fair value falls below carrying amount.

Outlook

Liquidity Sufficient Twelve Months Cash from operations and reserves expected to provide sufficient liquidity for the next twelve months, despite higher debt.

Finalizing Irwin Asset Valuation Company actively reviewing models for provisional goodwill and intangible assets from the August 8, 2025 Irwin acquisition.

Interest Rate Swap Executed Entered $20,000K interest rate swap to fix approximately 50% of variable rate term loan exposure until August 2030.

Rationalizing Advertising Spend Ongoing efforts focus on rationalizing advertising spend on less effective campaigns while increasing spend on core brands.

Peer Comparison

Revenue (TTM)

HAIN

$1.51B

-9.5%

NATR

$480.14M

+5.7%

BRCC

$398.26M

+1.7%

Gross Margin (Latest Quarter)

EWCZ

95.9%

-9.0pp

LFVN

74.0%

+1.1pp

NATR

72.5%

+1.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
NATR	$433.19M	22.2	12.2%	7.2%
EWCZ	$313.59M	29.0	11.4%	52.7%
BRCC	$292.24M	-9.0	-41.5%	14.2%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

16.1%

Strong Growth

4Q Net Income CAGR

-23.7%

Declining Profitability

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Mar 26, 2026

EPS:$0.25

Revenue:$27.02M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data